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ABSTRACT 
 At the Berkeley Structural Genomics Center (BSGC), our goal is to obtain a near-
complete structural complement of proteins in the minimal organisms Mycoplasma genitalium 
and M. pneumoniae, two closely related pathogens. Current targets for structure determination 
have been selected in six major stages, starting with those predicted to be most tractable to 
high throughput study and likely to yield new structural information.  We report on the 
process used to select these proteins, as well as our target deselection procedure.  Target 
deselection reduces experimental effort by eliminating targets similar to those recently solved 
by the structural biology community or other centers.  We measure the impact of the 69 
structures solved at the BSGC as of July 2004 on structure prediction coverage of the M. 
pneumoniae and M. genitalium proteomes.  The number of Mycoplasma proteins for which the 
fold could first be reliably assigned based on structures solved at the BSGC (24 M. pneumoniae 
and 21 M. genitalium) is approximately 25% of the total resulting from work at all structural 
genomics centers and the worldwide structural biology community (94 M. pneumoniae and 86 
M. genitalium) during the same period.  As the number of structures contributed by the BSGC 
during that period is less than 1% of the total worldwide output, the benefits of a focused 
target selection strategy are apparent.  If the structures of all current targets were solved, the 
percentage of M. pneumoniae proteins for which folds could be reliably assigned would 
increase from approximately 57% (391 of 687) at present to around 80% (550 of 687), and 
the percentage of the proteome that could be accurately modeled would increase from 
around 37% (254 of 687) to about 64% (438 of 687).  In M. genitalium, the percentage of the 
proteome that could be structurally annotated based on structures of our remaining targets 
would rise from 72% (348 of 486) to around 76% (371 of 486), with the percentage of 
accurately modeled proteins would rise from 50% (243 of 486) to 58% (283 of 486).  
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Sequences and data on experimental progress on our targets are available in the public 
databases TargetDB and PEPCdb. 
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BACKGROUND 
 
 M. genitalium and M. pneumoniae were the first-sequenced members of the class 
Mollicutes, a group of wall-less prokaryotes distinguished by their small genome sizes; the 
latter characteristic has earned them the name “minimal organisms” 1,2.  Minimal organisms 
have been the subject of numerous experimental and computational genomic studies 
because of the possibility of identifying the minimal complement of genes necessary for life 
3-5.  Because of their tractable size, organisms with minimal genomes have also been popular 
for structure and function prediction 2,6-13. 
 
 Structural genomics is an international effort to determine the three-dimensional 
shapes of all important biological macromolecules, with a primary focus on proteins.  Most 
approaches involve coarse-grained sampling of protein families, aiming to provide one 
structure from each family, allowing folds of all family members to be recognized by 
homology 14.  Several strategies for selecting proteins as targets have been proposed, 
including selecting all proteins in single genome 15-17, selecting proteins that will allow a 
maximal number of sequences to be modeled at some level of reliability 18-21, or selecting 
proteins of biological interest such as those from important biochemical pathways 22 or those 
thought to be unique to a particular species (ORFans) 23.  Details of these target selection 
strategies have been reviewed extensively 14,24-29, and implications of future selection 
strategies are discussed elsewhere 30. 
 
 In the United States, the National Institutes of Health are supporting structural 
genomics projects at 9 pilot centers through the Protein Structure Initiative (PSI).  Our work 
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is in the Berkeley Structural Genomics Center (BSGC), one of these 9 centers.  The BSGC 
began in September 2000, and this is a report on progress to date.  Our aim is to obtain a 
near-complete structural complement of the proteins in M. pneumoniae and M. genitalium.  As 
M. pneumoniae proteins are largely a superset of the proteins found in M. genitalium 31, target 
selection is focused on the former proteome.  Because of the relatively small size of these 
proteomes, it was expected that determining structures for most of the experimentally 
tractable proteins would be possible within the 5-year pilot period.  Obtaining a near-
complete structural complement of a single proteome would have the potential to enable 
new avenues of research that depended on this completeness.  This would be analogous to 
the research into non-coding regions of DNA that has been enabled by the availability of 
complete genome sequences.  Targets for the BSGC have been chosen in several stages:  
targets seen as “low hanging fruit” were attempted first, and later stages have targeted 
proteins predicted to be more experimentally difficult.  Targets in later rounds were also 
chosen using more sophisticated bioinformatic analyses, such as domain prediction, which 
were not in place at the beginning of the project.  Finally, target selection methods were 
refined somewhat, in response to early experience gained at our center and others.  For 
example, in later target selection rounds more targets related to a single Mycoplasma protein 
were chosen to be experimentally studied in parallel. 
 
 One important aspect of target selection that was not fully appreciated until the 
project was underway was the need for target deselection.  In the BSGC, we are only seeking 
to solve structures of proteins for which the structure can not be reliably predicted via 
bioinformatic methods.  As new structures are constantly being solved by structural biology 
and structural genomics groups worldwide, it is necessary to frequently reexamine our target 
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list and remove targets for which the structures of similar or identical proteins have been 
solved elsewhere.  We devised an automated procedure for identifying likely candidates for 
target deselection.  These candidates are manually examined at weekly meetings to determine 
if they should in fact be stopped or whether the information that could be gained by 
finishing the structure is worth the effort.  In this report, we examine the impact of target 
deselection and the reasons targets have been deselected. 
 
 Each round of target selection has led to successively more coverage of the M. 
pneumoniae proteome.  In this report, we quantify the degree of coverage on two levels.  First, 
we examine the percentage of the proteome that could accurately be modeled.  This requires 
at least 30% sequence identity between the experimentally solved target and the Mycoplasma 
protein.  Second, we estimate the percentage of the proteome for which the general fold can 
be predicted by homology with reasonable accuracy, whether or not there is sufficient 
confidence in the alignment accuracy to enable accurate structural modeling.  The latter is 
described as “coarse” coverage of protein sequence space, and the former as “fine” coverage 
(see http://grants2.nih.gov/grants/guide/rfa-files/RFA-GM-05-001.html).  Both of these 
percentages are calculated on a per-protein, where a protein is covered if any part can be 
structurally predicted, and per-residue, where we consider the ability to model each amino 
acid. 
 
 We also examine how successful the structural biology and structural genomics 
communities have been in advancing structural coverage of the M. pneumoniae proteome (at 
both “coarse” and “fine” degrees of coverage) and what role the BSGC has played.  Finally, 
we discuss some of the remaining obstacles to obtaining complete structural coverage. 
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Complete data including sequences and experimental status of BSGC targets are available in 
the public databases TargetDB and PEPCdb 32. 
 
METHODS 
 
Target Selection 
 
 A structural genomics target is a protein whose structure is selected for experimental 
characterization.  BSGC targets include Mycoplasma proteins as well as their homologs from 
other prokaryotes.  In general, all rounds of target selection involved three common steps.  
We started each step with the set of 677 M. pneumoniae ORFs described in the original 
annotation of the genome 1.  (Note that additional ORFs have been identified more recently 
33, and the current set of 687 ORFs is used throughout the remainder of this report to 
evaluate progress towards completion of the proteome.)  Each ORF was then augmented 
with a family of homologs from available, fully sequenced prokaryotic genomes to make a 
target set.  First, all target sets recognizably homologous to proteins of known structure were 
removed from further consideration.  Next, target sets of proteins which were predicted to 
be unsuitable for high-throughput study (e.g., those with predicted transmembrane helices) 
were eliminated.  Finally, specific targets were chosen from among proteins in the remaining 
target sets.  The number of targets chosen per family, or parallelism, varied amongst selection 
rounds, as described below.  A summary of methods used in different stages of target 
selection are shown in Table I.  A typical round of target selection is described in more detail 
in Figure 1. 
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 To date, there have been 6 rounds of target selection.  The first round of targets, 
which were mainly chosen in the first year of BSGC operations, were selected using a variety 
of ad hoc methods, or because they were of interest to the BSGC experimentalists.  Some 
aspects of this round of target selection are described elsewhere 34.  In the second round, we 
introduced basic standardized methods, as explained in detail below.  In the third round, 
more sophisticated methods of detecting currently known structures were introduced, and 
thresholds for identifying proteins likely to be intractable for high-throughput study (e.g., 
length and percentage of low complexity or coiled coil) were increased in order to go beyond 
“low hanging fruit.”  In the fourth round, the parallelism was increased as BSGC 
experimentalists began deploying more high-throughput experimental methods, and it was 
noted that experimental success rates varied among similar targets from different species.  In 
the fifth round, we chose a specialized group of targets that were more challenging to clone 
using automated methods.  These targets presented difficulties specifically related to the 
genetic code used by Mycoplasma, as explained in detail below, but could not be ignored 
because more suitable homologs could not be identified.  Finally, the sixth round of targets 
was chosen using a domain identification procedure, with the purpose of identifying 
tractable domain targets within full-length proteins that were set aside by filters in earlier 
rounds. 
 
Identifying known structures 
 
 At the beginning of each round of target selection, all M. pneumoniae proteins and 
their homologs were considered potential targets.  These were then removed from 
consideration if they were detectably homologous to other proteins of known structure.  
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Similarity to known structures was detected by first assembling a database of known protein 
structures, the “knownstr” database, which was updated prior to each target selection round.  
This database contained sequences of proteins released by PDB 35, sequences of proteins 
deposited in the PDB and made available while the structure is still “on hold,” and sequences 
from TargetDB 32, for which a structure has been solved by another structural genomics 
center.  We also included sequences of BSGC targets that have progressed to the “Traceable 
Map” stage, as this usually indicates the structure will soon be completed. 
 
 During each automated target selection round, sequences of all M. pneumoniae ORFs 
were compared to the knownstr database using several sequence comparison tools.  PSI-
BLAST 36 was used in rounds 2-6.  PSI-BLAST position-specific scoring matrices (PSSMs) were 
constructed for each M. pneumoniae ORF (or predicted domain in round 6) using 10 rounds of 
searching our “snr” database with a matrix inclusion threshold E-value of 10-2 (the default 
value of 5x10-3 was used in round 2).  The snr database included all sequences in the 
swissprot, trembl, and trembl_new files (downloaded 30 July 2001 for round 2, 30 
November 2001 for round 3, 21 October 2002 for rounds 4-5, and 26 February 2004 for 
round 6) from Swiss-Prot 37, which had been filtered with the SEG 38 and PFILT 39 programs 
using default options.  The filtering was done to reduce the chance of profile corruption 40, 
which can lead to inaccurate results.  The PSSMs were used to search the knownstr database, 
and any hits with an E-value of 10-1 or below were eliminated from consideration as targets.  
This significance threshold was chosen to increase the likelihood of detecting more remote 
homologs, even though it had some risk of false positives being removed from the target list.  
After the second round, the matrix inclusion threshold was increased in order to increase the 
possibility of identifying remote homologs, at the risk of a higher rate of corrupted PSSMs.  
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Because of the latter possibility, we also used BLAST 41 and Pfam 42 in target selection rounds 
3-6.  All M. pneumoniae ORFs with a BLAST hit against knownstr with an E-value of 10-1 or 
below were eliminated from consideration as targets, in addition to those already eliminated 
by PSI-BLAST.    In using Pfam to detect known structures, the HMMER tool (version 2.2g in 
rounds 3-5, 2.3.2 in round 6) 43 was used to compare the Pfam_ls library of hidden Markov 
models to both the knownstr database and the database of M. pneumoniae ORFs, using the 
family-specific “trusted cutoff” score as a cutoff for assigning significance.  We eliminated 
from consideration all ORFs that had a significant hit to a Pfam family that had also matched 
at least one known structure.  
 
Identifying targets predictably intractable for high-throughput study 
 
 As the next step in each target selection round, we eliminated M. pneumoniae proteins 
and domains that were likely to be either uninteresting or predictably intractable for high-
throughput study.  These included proteins with regions of amino acids predicted to be in 
transmembrane segments, coiled coils, regions of low complexity.  We also eliminated 
potential targets that were long and therefore likely to be challenging; in earlier rounds (1-2) 
of target selection, the length cutoff was 400 amino acids, and in later rounds (3-6) it was 
increased to 700 amino acids.  Finally, we excluded proteins annotated as ribosomal 
components, as these were expected to be unlikely to be stable in the absence of binding 
partners. 
 
 The SEG program 38 (version dated 24 May 2000) was run on all sequences to identify 
putative low complexity regions.  Default options were used.  In the round 2 of target 
 10
selection, any predicted low complexity region eliminated the ORF from consideration; in 
rounds 3-6, low complexity was allowed if the total length of low complexity regions did not 
exceed 20% of the total length of the protein (or domain in round 6). 
 
 The CCP program (written by J Kuzio at NCBI, version dated 14 June 1998), using the 
algorithm of Lupas 44, was used to predict coiled coil regions in all sequences.  Default 
options were used.  Thresholds for eliminating potential targets based on coiled coil 
predictions were the same as those used for low complexity regions (above). 
 
 Two programs were used to identify transmembrane regions.  TMHMM 2.0a 45 was 
used, with all default options.  PHDhtm 46 version 2.1 (October 1998) was also used, with the 
option optHtmisitMin (an option affecting the rate of false positive transmembrane 
predictions) set to 0.8.  Any transmembrane region predicted by either protein eliminated a 
M. pneumoniae ORF from consideration as a target in rounds 2-5.  In round 6, transmembrane 
predictions were used in assigning domain boundaries (see below). 
 
Identifying domains 
 
 Some Mycoplasma ORFs that were filtered out in early selection rounds were 
multidomain proteins that included tractable domains of unknown structure, but had been 
eliminated because of homology to a single domain of known structure.  Therefore, in round 
6, Mycoplasma ORFs were divided into domains before entering the target selection filters.  
The procedure used was the same as that used to identify domains in the ASTEROIDS data set 
of the ASTRAL database 47.  Hidden Markov models of ASTRAL families and superfamilies 
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were used to predict domains in the M. pneumoniae ORFs, using the HMMER tool with a 
significance cutoff of 10-4.  BLAST was also used to compare ASTRAL sequences to all M. 
pneumoniae ORFs, using a significance cutoff E-value of 10-4.  Regions of Mycoplasma sequence 
matching one or more ASTRAL sequences or hidden Markov models were annotated as 
belonging to the same SCOP 48 superfamily as the hit with the most significant E-value 
produced by either method.  Remaining unclassified regions were annotated using Pfam 
10.0, using the Pfam_ls model library and the “trusted cutoff” score for each model to 
determine significance.  Significant hits were annotated as Pfam domains.  After Pfam 
annotation, remaining regions of at least 20 consecutive residues were annotated as potential 
unclassified domains.  This procedure is identical to the one documented in the release notes 
for ASTRAL 1.65. 
 
 Putative domains identified by the ASTRAL procedure were further split into two 
parts at the end of each predicted transmembrane helix, as predicted by TMHMM 2.0a 45.  
Finally, putative domains shorter than 50 residues were eliminated from further 
consideration as targets. 
 
Identifying particular proteins as targets 
 
 In addition to the M. pneumoniae proteins themselves, homologous proteins from 
other prokaryotes were also chosen as targets.  Each M. pneumoniae protein (or predicted 
domain in round 6) that passed through the above filters was used to search the NCBI 
database of proteins from sequenced bacterial and archaeal genomes 
(ftp://ftp.ncbi.nih.gov/genomes/Bacteria), although targets were only chosen from 
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genomes for which the BSGC had access to purified genomic DNA.  A list of all genomes 
from which homologous targets were chosen is given in Table S1 in the supplementary 
information.  To find these homologs, PSI-BLAST 36 was used in rounds 2-3 (version 2.2.1) 
and 4-6 (version 2.2.4).  PSI-BLAST PSSMs were constructed for each M. pneumoniae ORF using 
10 rounds of searching the nonredundant sequence database “snr” (as described above) with 
default parameters; the PSSMs were then used to search the database of genomes.  BLAST 
version 2.2.4 was also used (with default parameters) in rounds 4-6 to search the genome 
database.  All proteins identified by BLAST or PSI-BLAST with E-values more significant than 
10-4, with the region of local similarity covering at least 50 residues, were considered as 
possible targets.  In round 6, predicted domains from M. pneumoniae were used to search for 
possible targets.  In this case, only the local region of the homologous ORF was selected as a 
possible target, and we also required that the region of local similarity identified by BLAST or 
PSI-BLAST to cover at least 80% of the length of the putative M. pneumoniae domain.  This 
latter restriction was intended to decrease the possibility of selecting a fragment of a domain 
as a target. 
 
 Once potential targets were identified for each M. pneumoniae ORF or putative 
domain, we selected a limited number from each family as targets.  The maximum number 
of targets chosen for each M. pneumoniae ORF was limited to 4 in earlier rounds (2-3) of target 
selection, but expanded to 10 in later rounds (4-6), after better automation became available 
in the BSGC experimental pipeline.  Those targets were chosen as follows. 
 
 Potential targets from M. pneumoniae were always selected if they passed an additional 
screen to ensure they could be expressed in the E. coli expression system used at the BSGC.  
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M. pneumoniae 49 and other related mollicutes such as Ureaplasma urealyticum 50 can use UGA 
codons to encode the amino acid tryptophan, whereas UGA is a stop codon in E. coli.  Thus, 
cloned M. pneumoniae proteins with this codon would express truncated proteins in E. coli.  In 
cases where a UGA codon was within about 30 bases of either end of the gene, it could easily 
be mutated to a UGG codon during cloning, using mutating PCR primers.  Other UGA 
codons, called internal UGA codons, could only be mutated in a more difficult multi-step 
cloning procedure.  In rounds 1-4, targets with a maximum of 1 internal UGA codon were 
allowed.  In round 5, this restriction was relaxed to allow 2-4 internal UGA codons.  In round 
6, because we wanted to clone targets using a fully automated protocol, no internal UGA 
codons were allowed. 
 
 The next highest priority targets to be selected were from thermophiles and 
halophiles, as these were expected to be experimentally more tractable, for example being 
partially purified by heating E. coli lysate 51.  These targets, if available, were chosen in order 
by significance of the BLAST or PSI-BLAST similarity score.  If the maximum number of 
targets per M. pneumoniae ORF had not been reached after choosing these targets, additional 
targets were chosen from mesophilic organisms, including other paralogs from M. 
pneumoniae.  These were also chosen in order by significance, with the additional restriction 
that the sequences had to be at least 30% identical over an aligned region of at least 50 
consecutive residues.  The latter restriction was intended to ensure that a reasonably accurate 
model could be produced for the M. pneumoniae ORF if the structure of the mesophile protein 
were to be solved.  Current state-of-the-art comparative modeling methods are able to 
produce models of medium accuracy (about 90% of the main chain modeled to within 1.5 Å 
RMS error) when sequence identity between the model and the template is at least 30%; 
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below this threshold, alignment errors increase rapidly and become the major source of 
modeling error 52.    
 
Target Deselection 
 
 Because the BSGC only seeks to solve structures for protein domains for which the 
structure cannot be reliably predicted via bioinformatic methods, we need to frequently 
check whether structures similar to our targets have been solved by other groups.  We stop 
targets for which structures of similar proteins have been solved.  Most deselection analysis 
steps are automated.  However, the final decision on whether to stop any target is performed 
manually.  This automated analysis and manual review are both performed weekly. 
 
Automated analysis 
 
 The automated analysis begins with using BLAST and PSI-BLAST to compare our 
current target sequences to the knownstr database (described above), which is updated 
weekly.  PSI-BLAST PSSMs are constructed for each target using 10 rounds of searching the 
“snr” nonredundant sequence database (described above) with a matrix inclusion threshold 
E-value of 10-2.  These PSSMs are used to search the knownstr database, and all hits with an 
E-value of 10-2 or better result in flagging the region of target sequence corresponding to the 
hit.  BLAST hits against knownstr with E-values of 10-2 or better also result in flagging the 
region of sequence corresponding to each hit.  These thresholds were chosen empirically, 
with the goal of being sensitive enough to detect remote homology while minimizing the 
time spent examining false positives. 
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  After target residues are flagged, those proteins that possess at least one region of 50 
consecutive residues not flagged by hits are automatically left in the structural genomics 
pipeline.  This is because even if some parts of a target are found to be similar to proteins of 
known structure, the remaining region may potentially contain a domain for which no 
reliable prediction of structure could be made through the bioinformatic methods used.  
Targets that are similar to proteins of known structure over virtually their entire length 
(without a stretch of 50 consecutive residues not flagged by hits) are identified for manual 
review to determine whether these targets should be deselected. 
 
Manual review of target deselection candidates 
 
 Because the bioinformatic procedure above may result in false positives, targets 
identified by the procedure are manually examined to determine if work should be stopped.  
The decision about whether to stop work on a target is made by the experimentalists 
working on the target and reflects a cost-benefit analysis of how much work would be 
required to finish the structure versus the potential for new information to be gained.  This 
decision is informed by the degree of sequence similarity with the known structure(s) and 
implications for accuracy of a comparative homology model, and whether functionally 
important residues in the known structure are conserved in the target.  Generally, targets that 
have been crystallized are not deselected when the structure of a similar protein has been 
solved, because after data collection, the target structure may easily be solved using 
molecular replacement.  If a target has not been purified, it is generally stopped if the fold 
prediction is thought to be reliable, even if the similarity is insufficient to allow accurate 
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modeling.  Targets that have been purified but not crystallized are usually stopped only if an 
accurate model can be constructed, and if crystallization trials are proceeding poorly. 
 
 After a decision is made on whether to deselect or continue work on the target, the 
decision is recorded.  If the target is continued, it is not recommended again for deselection 
by the automatic procedure unless a new structure is solved that is identified as similar to the 
target.  We are identifying ways to automatically perform much of the review process, in 
order to more quickly process larger numbers of targets. 
 
Quantifying coverage of Mycoplasma proteomes 
 
 The ultimate goal of structural genomics is to provide structural information for the 
complete repertoire of biological macromolecules.  In this report, we measure progress 
towards that goal as “coverage,” the fraction of sequences or residues in a set (such as a 
proteome) for which structural information is available or can be inferred.  If a region of 
sequence is at least 30% identical to a protein with experimentally determined three-
dimensional structure, the region is considered covered at a “fine” level.  If homology is 
detectable, regardless of sequence identity, the region is considered covered at a “coarse” 
level.  Details of these calculations are described below. 
 
 Per-sequence coverage of a proteome was measured as the fraction of sequences in 
the proteome that have at least one region covered by structural annotation.  Per-residue 
coverage was calculated by dividing the number of residues covered by structural 
annotations by the total number of residues.  In the latter case, all residues between the 
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endpoints of a local alignment (e.g., from BLAST or Pfam) were treated as covered by the 
annotation, whether they are aligned to a residue or a gap.  We also estimated the per-residue 
coverage of regions of the proteome predicted to be “HT-tractable and interesting” when 
using high-throughput (HT) experimental methods for structure determination.  For this 
calculation, we excluded regions predicted to be transmembrane, low complexity, or coiled 
coil, as well as short interstitial regions (fewer than 50 residues) between predicted 
transmembrane regions and regions of structural annotation.  The actual number of such 
residues in each proteome varies slightly in each calculation, as the interstitial regions change 
depending on which regions are annotated as matching a domain of known structure.  For 
example, there are more regions annotated as covered at a coarse level than at a fine level, so 
there are additional residues in short interstitial regions in the latter calculation.  However, in 
general, the number of predicted HT-tractable and interesting residues is about 85% of the 
total number of residues in each proteome.  Predictions of low complexity, coiled coil, or 
transmembrane regions were performed during target selection, as described above.  We 
report both variants of per-residue coverage in tables. 
 
 Our analysis of coverage is based on an updated annotation of the M. pneumoniae 
genome 33, which includes 687 proteins and 239,722 residues.  We also measured coverage of 
the M. genitalium proteome 2, which is annotated as containing 486 proteins and 175,930 
residues. 
 
 As a baseline, we calculated coverage of the M. pneumoniae and M. genitalium 
proteomes by known structures prior to the establishment of the BSGC on 1 September 
2000.  We then measured coverage by structures solved by the BSGC, as well as coverage that 
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would result if structures of targets selected in each round of target selection were 
successfully completed.  Finally, we measured coverage by all current structures (as of 13 July 
2004) in order to determine the relative impact of the BSGC’s efforts. 
 
  Coarse coverage was evaluated using BLAST (2.2.4), PSI-BLAST (2.2.4), and Pfam 10.0.  
BLAST was used with default parameters to search each M. pneumoniae ORF against the 
knownstr database and a database of BSGC targets.  A PSI-BLAST PSSM was constructed for 
each M. pneumoniae and M. genitalium ORF using 10 rounds of searching the snr nonredundant 
sequence database (as described above, downloaded 26 February 2004) with default 
parameters; the PSSMs were then used to search the knownstr database and the database of 
BSGC targets.  An E-value cutoff of 10-4 was used as a threshold for evaluating significance 
for both BLAST and PSI-BLAST; for PSI-BLAST, this corresponds to about a 1% error rate in 
genome annotation 53,54.  The HMMER tool (version 2.3.2) 43 was used to compare the 
Pfam_ls library of hidden Markov models from Pfam 10.0 to the knownstr database, the 
database of M. pneumoniae and M. genitalium ORFs, and the database of BSGC targets, using the 
family-specific “trusted cutoff” score as a cutoff for assigning significance.  Local regions of 
these sequences were assigned as matching each other if they both had significant matches to 
the same Pfam family. 
 
 Fine coverage was evaluated using the subset of coarse coverage results produced by 
BLAST and PSI-BLAST for which the percentage identity calculated by (PSI-) BLAST was above 
30% in the region of alignment. 
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RESULTS 
 
Experimentally difficult regions of Mycoplasma proteomes 
 
 The focus of BSGC effort is on aspects of the M. pneumoniae proteome which are both 
interesting and tractable to high-throughput (HT) methods of structure determination.  This 
encompasses the whole proteome of 687 ORFs, excluding all regions predicted to span the 
membrane, coiled coil regions, short loops between domains, and low complexity regions.  
Of the 687 ORFs in M. pneumoniae, 149 (21.7%) have at least one predicted transmembrane 
helix.  33 of 687 proteins (4.8%) have at least 20% of their sequence predicted as coiled coil, 
and 43 of 687 proteins (6.3%) have at least 20% of their sequence predicted as low 
complexity.  A total of 201 of 687 proteins (29.3 %) were considered intractable to high-
throughput study due to meeting at least one of these three criteria.  A total of 14.8% of the 
residues in the proteome (35,419/239,722) are in regions predicted to be either low 
complexity, coiled coil, or transmembrane helix, and thus either uninteresting or 
experimentally difficult to solve using high-throughput methods of structure determination.  
An additional 3,133 residues (1.3%) in the proteome are in short (<50 residue) interstitial 
regions between transmembrane helices and currently known structures (at the coarse level 
of similarity).  The percentages are similar for M. genitalium.  Of 486 ORFs, 111 (22.8%) have 
at least one predicted transmembrane helix, 19 (3.9%) have at least 20% predicted coiled 
coil, and 22 (4.5%) have at least 20% predicted low complexity.  A total of 136 of 486 
proteins (28.0%) were considered intractable to high-throughput study due to meeting at 
least one of the three criteria.  A total of 14.1% of M. genitalium residues (24,880/175,930) are 
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in regions predicted to be low complexity, coiled coil, or transmembrane helix, and an 
additional 738 residues (0.5%) are in the short interstitial regions described above. 
 
Coverage by BSGC targets 
 
 Coverage of the M. pneumoniae and M. genitalium proteomes by structures released 
prior to the establishment of the BSGC on 1 September 2000, and by targets in each round of 
target selection to date, are shown in Table II.  Only 142 of 687 M. pneumoniae proteins 
(20.7%) and 20.5% (39,448/192,673) of the predicted HT-tractable and interesting residues 
could be accurately modeled based on structures available prior to BSGC establishment.  
More than twice as many--297 of 687 proteins (43.2%), or 43.1% (84,324/195,732) of the 
HT-tractable and interesting residues--could be reliably assigned to a fold at that time.  A 
higher fraction of M. genitalium proteins were covered:  137 of 486 proteins (28.8%) and 
26.6% (37,855/142,422) of HT-tractable and interesting residues could be modeled, while 
262 of 486 proteins (53.9%) and 52.4% (75,936/144,943) of HT-tractable and interesting 
residues could be reliably assigned to a fold. 
 
 The first round of preliminary and manually selected targets produced the greatest 
incremental increases in coverage.  However, the parallelism in this target set was low:  an 
average of only one to two targets were selected for each Mycoplasma protein of interest. 
 
 The next three sets of automatically selected targets each provided incremental 
improvements in coverage, as well as a deliberate increase in the parallelism in the pipeline.  
In rounds 2-3, up to four targets were chosen for each M. pneumoniae protein of interest, 
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counting targets already chosen in other rounds and to cover other M. pneumoniae proteins.   
This increased the average number of targets per protein to more than 3, although there 
were some cases where fewer than four homologs could be found that met our criteria to be 
targets.  In cases where multiple paralogs of a gene existed within M. pneumoniae, the number 
of targets per Mycoplasma ORF was sometimes more than 4, as targets chosen to cover one 
paralog might also be similar to others.  In round 4, the maximum number of targets chosen 
per M. pneumoniae protein was increased to 10.  However, this did not increase the actual 
redundancy in the pipeline as much as expected, as nearly all available homologs meeting our 
criteria as targets had already been chosen. 
 
 In the 4th round of target selection, 65 potential targets were eliminated by the filter 
that prevented targets with more than 1 internal UGA codon from being chosen.  However, 
46 of these rejected targets were M. pneumoniae proteins with no more tractable homologs in 
our dataset.  In round 5, the UGA codon limit was relaxed from 1 to 4 internal UGA codons 
permitted in order to target some of these proteins using a more complex multi-step cloning 
approach to mutate each of the codons to UGG.  While 33 of the 46 previously rejected 
targets were selected in this round, the other 13 had between 5 and 21 internal UGA codons, 
so were judged to be too difficult for this technique to succeed in a manner suitable for 
structural genomics.  The 33 targets chosen led to a significant increase in coverage of M. 
pneumoniae:  37-43 more proteins and 10-12% more residues depending on whether coverage 
is measured at the coarse or fine level.  This step had a smaller impact on coverage in M. 
genitalium (only 13 more proteins) as most targets chosen in round 5 were unique to M. 
pneumoniae. 
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 In the 6th round of target selection, individual predicted domains were selected 
instead of full length targets, in order to increase the number of potential tractable targets.  
Domain prediction resulted in greater coverage of the Mycoplasma proteomes as well as more 
than doubling the parallelism in the experimental pipeline.  We expect some failures of these 
targets due to inaccurate prediction of domain boundaries:  a preliminary analysis based on 
successive versions of SCOP showed that the domain prediction method accurately predicts 
65% of the domain boundaries to within 10 residues of the manually assigned boundaries in 
SCOP, and 80% of the boundaries are correctly predicted within 20 residues (unpublished).  
In addition, some domains are unable to fold on their own, even if the boundaries are 
correctly identified.  However, the increased parallelism in the pipeline should partially 
alleviate these potential problems.  Preliminary experimental success rates for these targets 
are reported as supplementary information. 
 
Mycoplasma residues remaining uncovered by targets 
 
 After 6 rounds of target selection, current BSGC targets cover 550 of 687 M. 
pneumoniae proteins (80.1%) and 78.7% (161,281/204,812) of the HT-tractable and interesting 
residues at the coarse level.  The remaining regions not covered by BSGC targets form 230 
continuous stretches of sequence at least 50 residues long.  Of these, 121 contain 1 or more 
internal UGA codons, so were not chosen as targets during the last round of target selection.  
These may be selected in future rounds of target selection, as the UGA problem may be 
solved by using other expression systems or by cloning homologs from other bacteria.  The 
other 109 regions contain more than 20% predicted coiled coil or low complexity regions, or 
at least one transmembrane helix, which would prevent them from being chosen as targets 
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under our current criteria.  While the coiled coil or low complexity residues in each region 
are not considered “HT-tractable and interesting,” the other residues in each region are.  One 
of these regions is the ribosomal protein S21, which was excluded due to potential inability 
to fold in the absence of binding partners, but which is not part of current ribosomal 
structures.  The remaining 109 regions may prove to be intractable to high throughput 
studies. 
 
 Of the 687 M. pneumoniae proteins, 223 (32.5%) have no homologs outside of other 
Mycoplasma and Ureaplasma species, and 54 (7.9%) are ORFans 23, having no homologs outside 
M. pneumoniae.  Of the 230 remaining regions in M. pneumoniae not covered by targets, 83 
(36%) are in proteins that have no homologs outside of other Mycoplasma and Ureaplasma 
species, and 14 (6.1%) are in ORFans.  Therefore, the remaining regions do not appear to be 
biased towards ORFans.   For most of the 121 regions currently not selected due to UGA 
codons, it is likely that targets may be chosen from other species when additional genomic 
DNA becomes available. 
 
Current structural coverage, and impact of BSGC 
 
 As shown in Table III, coarse structural coverage of the M. pneumoniae proteome has 
increased from 297 of 687 proteins (43.2%) in 1 September 2000 to 391 of 687 proteins 
(56.9%) due to the solution of experimental structures since the start of the BSGC.  Coverage 
measured as a fraction of interesting and HT-tractable residues has increased over the same 
time period from 43.1% (84,324/195,732) to 59.4% (119,433/201,170).  Fine coverage has 
increased from 142 of 687 proteins (20.7%) to 254 of 687 proteins (37.0%), or from 20.5% 
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(39,448/192,673) to 36.7% (71,405/194,362) of the interesting and HT-tractable residues.    
This represents a near doubling of fine coverage, as well as a significant increase in coarse 
coverage. 
 
 To date (as of 13 July 2004), the BSGC has solved 69 structures of 51 different targets 
(some of the structures are for the same targets, under different conditions or with bound 
ligands).  A disproportionate number of the solved structures to date have been from 
thermophiles (32 of 51 solved targets, or 63%, versus 284 of 945 total targets, or 30%), 
which were usually selected to cover M. pneumoniae proteins at a coarse rather than fine level.  
Therefore, BSGC structures have had more of an impact on coarse coverage of the proteome 
than on fine coverage.  The relative impact of BSGC structures on coverage of Mycoplasma 
proteomes is illustrated in Figure 2.  Coarse coverage of M. pneumoniae has increased by 29 
proteins (4.3% of the 687 proteins in the proteome) due to BSGC structures, while increasing 
by 83 proteins (12.1%) due to all non-BSGC structural genomics and structural biology efforts 
over the same time period.  There is significant overlap between the two groups:  targets 
similar to 18 M. pneumoniae proteins were solved by both BSGC and non-BSGC groups.  In 13 
of these 18 cases, the BSGC solved and released the target structure prior to the other groups.  
However, even under the assumption that structures similar to all 18 M. pneumoniae proteins 
would have been solved in the absence of the BSGC, the 11 M. pneumoniae proteins covered 
by targets solved only at the BSGC account for 11.7% (11 of 94 proteins) of the total increase 
in coarse coverage.  The 24 structures solved either solely or first at the BSGC account for 
25.5% (24 of 94) of the total increase in the number of proteins with coarse coverage over 
the lifetime of the BSGC to date.  Similarly, coarse coverage of M. genitalium has increased 
from 262 proteins (53.9% of the 486 proteins in the proteome) to 348 proteins (71.6%).  
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Coverage of interesting and HT-tractable residues in M. genitalium increased from 52.4% 
(75,936/144,943) to 72.0% (108,155/150,312).  BSGC efforts account for coverage of 25 M. 
genitalium proteins, 16 of which were also covered by structures solved elsewhere (although 
12 of the 16 were first covered by BSGC structures).  The 9 proteins for which targets were 
solved only at the BSGC represent 10.5% (9 of 86) of the total increase in coarse coverage of 
M. genitalium over the lifetime of the BSGC, while the 21 proteins solved either solely or first 
at the BSGC account for 24.4% (21 of 86) of the total increase in M. genitalium proteins 
covered. 
 
 While fine coverage of both Mycoplasma proteomes increased by a smaller amount 
due to BSGC structures, there was less overlap with structures solved by other groups.  Fine 
coverage of M. pneumoniae has increased by 20 proteins (2.9% of the 687 proteins in the 
proteome) due to BSGC structures, while increasing by 98 proteins (13.2%) due to all other 
structures solved over the same time period.  Only 6 proteins overlap between the two 
groups, and in 4 of these 6 cases, the BSGC solved the target prior to the other groups.  The 
14 M. pneumoniae proteins covered only by BSGC structures account for 12.5% (14 of 112) of 
the total increase in fine coverage of the proteome, and the 18 proteins covered solely or 
first by BSGC targets account for 16.1% (18 of 112) of the increase.  Fine coverage of M. 
genitalium has increased from 137 proteins (28.2% of the 486 proteins in the proteome) to 
243 proteins (50%) over the lifetime of the BSGC.  Coverage of the interesting and HT-
tractable residues in M. genitalium has increased from 26.6% (37,855/142,422) to 47.1% 
(67,9705/144,024) during the same time period.  BSGC efforts account for coverage of 17 M. 
genitalium proteins, 7 of which were also covered by structures solved elsewhere (5 of the 7 
were first covered by BSGC structures).  The remaining 10 proteins represent 9% (10 of 106) 
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of the total increase in fine coverage of M. genitalium over the lifetime of the BSGC; proteins 
solved solely or first by the BSGC account for 14.2% (15 of 106) of the increase. 
 
 It is interesting to contrast the increased coverage of Mycoplasma provided by BSGC 
structures with coverage provided by one of the most impressive structural biology 
achievements made at about the same time the BSGC was getting underway: high-resolution 
structures of the ribosome 55-57.  Some individual ribosomal proteins had been solved prior to 
the first of these studies, and these prior structures contributed to fine coverage of 17 M. 
pneumoniae proteins (2.5% of the 687 proteins in the proteome) and coarse coverage of 21 
proteins (3.1% of the proteome).  Ribosomal structures currently contribute to fine coverage 
47 proteins in M. pneumoniae (6.8% of the 687 proteins), and coarse coverage of 57 proteins 
(8.3%).  Currently, all annotated ribosomal proteins in M. pneumoniae except L33 type 2, L28, 
and S21 are covered at least coarsely.  While ribosomal structures have had a greater impact 
on coverage than all structures solved at the BSGC, it is unlikely that any single 
macromolecular complex that is studied in the future will provide such an increase. 
 
Impact of target deselection 
 
 As of 1 June 2004, 324 separate target deselection recommendations had been issued 
by the automated system, an average of 2.4 per week since the system was deployed in 
October 2001.  146 of the suggestions were overridden, and 178 were followed, resulting in 
stopping work on a target.  Recommendations are automatically cancelled and re-issued if 
additional structural information becomes available prior to the recommendation being acted 
on, and these statistics do not include hundreds of such cases: multiple recommendations 
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before action was taken were treated as a single recommendation.  Many of the 
recommendations that were issued concerned the same targets:  the 146 overridden 
suggestions were issued on a total of 54 targets, and 30 of these targets were eventually 
stopped after two or more deselection recommendations.  Overall, recommendations were 
issued on 202 separate targets, of which 178 were deselected. 
 
 Most of the target deselection recommendations took place prior to the last round 
(round 6) of target selection on 22 March 2004, at a time when there were fewer than 400 
targets being actively worked on (neither stopped nor solved).  As there are currently almost 
700 active targets, we expect the number of recommendations to increase accordingly.  
Figure 3 shows the percentage of targets that were deselected over time, as a fraction of the 
cumulative number of targets chosen.  Figure 4 shows the stages at which targets were 
stopped:  49 of 178 (27.5%) were stopped after the target protein was purified.  About half 
(86 of 178, or 48.3%) of the targets were stopped because we solved a “parallel” target, and 
about the same number (87 of 178, or 48.9%) were stopped due to another structural 
genomics center or structural biology laboratory solving a structure.  Only five targets have 
been stopped solely due to experimental difficulty, although experimental difficulty is a 
factor taken into consideration during the manual review phase of target deselection. 
 
 65 of the 178 deselected targets (37%) were stopped based on the sequence of a 
homologous protein being released by the PDB, at the time of either the deposition or release 
of the structure.  In 13 of these cases, the recommendation to stop was based on a structure 
that was on hold and unavailable to us, but for which the sequence was available prior to the 
release of the structure.  In these cases, the time between release of the sequence and release 
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of the structure by the PDB ranged from 33 to 396 days, with an average hold time of 231.9 
days.  In these cases, the crystallographers’ decision to release their sequences at the time of 
deposition allowed us to stop these targets almost 8 months earlier on average than we could 
have if the sequences had not been made available.  In the other 52 cases, the sequence was 
not made available until the structure was also released.  In these cases, the hold times (time 
between deposition and release of the structure and sequence) ranged from 19 to 1,515 days, 
with an average hold time of 151.4 days.  Had the sequences of these 52 structures been 
made available at the time deposition to the PDB, the deselection recommendations could 
have been made almost 5 months earlier on average (and in the longest case, 1QGD, in which 
the structure was on hold for over four years, the BSGC targets would not have been 
selected). 
 
 To evaluate the impact of stopping work on 178 targets, we measured incremental 
coverage of the M. pneumoniae proteome at coarse and fine levels that would have resulted 
had the targets been solved, relative to the actual current coverage.  At a fine level, coverage 
would have been increased by 19 proteins (2.7% of the 687 proteins in the proteome, or 
2.5% of interesting and HT-tractable residues), and at a coarse level, coverage would have 
been increased by only 1 protein (0.1% of proteins, or 0.2% of the interesting and HT-
tractable residues).  This is not surprising, as the target deselection procedure focuses on 
remote homology; if finishing a target would lead to more coverage at a fine level but not at 
a coarse level, the target is usually stopped. 
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Impact on coverage of other proteomes 
 
 One of the secondary goals of choosing a minimal proteome as the focus of 
structural genomics efforts at the BSGC was to evaluate the impact on coverage of larger 
proteomes.  The idea is that a minimal proteome is a ubiquitous proteome, and that the 
complete structural complement of a minimal proteome would serve as a platform for 
understanding larger proteomes 15.  In an earlier Pfam-based study 30, we showed that 
maximum coverage across multiple species is obtained by solving structures from large 
families; solving structures of proteins not classified in large Pfam-A families has little impact 
on coverage of other species.  We used HMMER 43 to identify all Pfam-A (version 10.0) 
families in our solved targets, using the “trusted cutoff” for each family as a measure of 
determining significance.  Three of our solved targets had no hits in Pfam-A, and may 
represent small families restricted to a few bacteria.  Pfam-A families for which the BSGC 
solved the first structure are shown in Table IV.  All but two of these 24 families are larger 
than the median family size (36) in Pfam 10.0. 
 
 Using methods described elsewhere 30, we measured coverage in several other 
proteomes, as well as Swiss-Prot and TrEMBL.  Results are shown in Table V.  Most of the 24 
Pfam families match at least one family in each proteome; the total number of hits ranges 
from 20 in the M. jannaschii proteome to 100 in A. thaliana.  Overall, the 24 families hit a total 
of 1,122 proteins in Swiss-Prot (from Pfamseq 10.0) and 3,737 in Swiss-Prot and TrEMBL 
combined.  Thus, the families solved first or only at the BSGC are in fact nearly ubiquitous 
across a variety of commonly studied eukaryotic and prokaryotic proteomes.  Note that 
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BSGC structures added approximately 1% to the number of proteins covered in other 
prokaryotes such as E. coli, M. jannaschii, and M. tuberculosis. 
 
Cellular functions of targets 
 
 One of the goals of structural genomics is to study proteins of unknown function 
and “hypothetical proteins,” as the three-dimensional structures of these proteins often 
suggest biochemical or biophysical functions 58,59.  Biochemical and cellular functions of 
microbial proteins are annotated in the Comprehensive Microbial Resource 60.  The 
annotated functions of all M. pneumoniae and M. genitalium proteins, and our targets, are 
shown in Table VI. 
 
 As shown in Table VI, the majority of our targets (508 of  945, or 54%) are 
annotated as hypothetical proteins, unclassified function, unknown function, or not 
annotated.  Proteins in these categories also constitute the majority of M. pneumoniae proteins 
(363 of 687, or 53%) and a large fraction of M. genitalium proteins (195 of 486, or 40%).  
Proteins in this set have relatively little structural coverage:  only 35% of these M. pneumoniae 
proteins (127 of 363) and 50% of these M. genitalium proteins (97 of 195) are covered by 
current structures at a coarse level.  Only cellular envelope proteins (50 in M. pneumoniae and 
28 in M. genitalium) have less coverage, as expected since many of these proteins contain 
transmembrane regions.  Although TIGR role annotations were not explicitly considered 
when choosing targets, this analysis shows that most currently active targets correspond to 
roles which have the least amount of current structural coverage. 
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Current active targets 
 
 As of 13 July 2004, there are 649 current active targets (targets that have not been 
solved or stopped), as shown in Table I.  The distribution of experimental stages of these 
targets is shown in Table S2 and discussed further in the supplementary material.  Of these, 
the vast majority (459 of 649, or 71%) were selected in the most recent round, round 6, 
several months before.  In the prior three automated sets (rounds 2-4), approximately half of 
the targets (115/227) are still active, the remaining targets having been solved or stopped 
due to homology with a solved structure.  The overall fraction of targets for which the BSGC 
has solved a structure in these three rounds is approximately 8% (11% in round 2, 5% in 
round 3, and 8% in round 4, or 19/227 overall).  The fraction of solved targets is slightly 
higher in round 2, as expected since these targets have been active for the longest time.  No 
targets in the final two rounds (5-6) have been solved, as they have only been active for a 
few months.  The first round has a much higher fraction of solved targets:  structures for 32 
of 163 targets (20%) were solved.  We suspect this is due to two factors.  First, these targets 
have been in the experimental pipeline for longer, so there has been more time to work 
around experimental difficulties in a “multi-path” approach 61.  Second, these targets include 
some targets manually selected by experimentalists as interesting, and a share of the work in 
these cases was done by collaborators, allowing more attention to be focused on these 
targets.  The expected rate at which full-length targets will be solved in the future therefore 
probably lies somewhere between the 11% observed for round 2 and the 20% observed for 
round 1.  Because many targets in these two rounds were deselected due to a homolog being 
solved at the BSGC or elsewhere (83 of 163, or 51%, in round 1, and 38 of 92, or 41%, in 
round 2), this fraction of targets which have been solved represents a lower bound on the 
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percentage of targets which are tractable using our current methods.  We expect the fraction 
of solved structures for predicted domain targets to be somewhat lower than for full length 
targets, both because the targets themselves are expected to be relatively more difficult 
experimentally (for reasons described above) and because the parallelism in round 6 is 
higher, so more will be deselected as a result of solving a parallel target. 
 
DISCUSSION 
 
 We have documented the methods of target selection and deselection deployed to 
date at the BSGC, demonstrating an evolving strategy that started with “low-hanging fruit:” 
targets that are most likely to be tractable, and least similar to currently known structures.  In 
successive rounds of target selection, both more experimentally challenging targets as well as 
targets more similar to known structures were selected for experimentation.  We also 
succeeded in increasing the parallelism of targets in our pipeline, in response to reports that 
homologous proteins may exhibit very different degrees of tractability.  In practice, this 
appears to have been effective:  targets that were deselected because we solved a parallel 
target were at a variety of stages at the time one of the parallel targets was solved. 
 
 Our target deselection procedure has been very efficient in preventing the BSGC from 
spending effort on targets that would result in little incremental coverage of Mycoplasma 
proteomes.  However, a drawback of the procedure is that it requires a significant amount of 
human effort to manually examine new recommendations every week.  As we expect the 
required effort will scale almost linearly with the number of active targets, structural 
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genomics centers such as the BSGC will need to further automate target deselection as the 
overall throughput of structural genomics increases. 
 
 The automated procedure for recommending target deselection relies on timely 
availability of the sequences of newly solved structures.  One of the primary sources of data 
is the sequences of “on hold” structures from the PDB.  Upon deposition of a new structure, 
the authors of a PDB entry may choose whether to make the sequence available immediately 
or hide the sequence until release of the structure.  Of the 2722 structures awaiting release 
today (17 August 2004), the sequence is available for only 935; for those structures held for 
publication (1691 structures) or release on a future date (332), sequences are available for less 
than half (883/2022, or 44%).  More timely access to the remaining sequences, or the ability 
to compare structural genomics target sequences to hidden “on-hold” sequences, would 
enable more efficient use of resources by the BSGC and other structural genomics centers. 
 
 Our primary goal in target selection was coverage of the tractable and interesting 
portions of the M. pneumoniae proteome at a coarse level of similarity.  If all our current 
targets were solved, either at the BSGC or by the structural biology community, we would be 
approximately 80% of the way towards achieving that goal.  Of the remaining 20%, we 
estimate that approximately half could be targeted with high-throughput methods, if the 
procedure for introducing multiple point mutations during cloning were to be fully 
automated.  The remaining 10% of the proteome that has not been targeted to date consists 
of tractable and interesting regions closely linked to experimentally problematic regions such 
as low complexity or transmembrane regions, and therefore may prove more resistant to 
high-throughput methods.  It is also unlikely that all current targets in the pipeline are 
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actually tractable to high-throughput study, as some targets may be unstructured in the 
absence of a required partner or ligand. 
 
 Our focus on coarse coverage of the proteome has led to an impressive increase in 
coverage with a relatively modest number of solved structures.  In the nearly 4 years since 
September 2000, over 8,000 structures have been deposited to the PDB.  While the 69 
structures contributed by the BSGC account for less than 1% of that total, these structures 
account for approximately 25% of the total incremental increase in coarse structural 
coverage of the M. pneumoniae and M. genitalium proteomes during that time.  Structures 
solved by the BSGC include the only structural representatives for 10 Pfam-A families, and 
were the first structural representatives for 14 additional Pfam-A families.  These families are 
nearly ubiquitous across a wide variety of eukaryotic and prokaryotic proteomes. 
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FIGURE LEGENDS 
 
Figure 1:  Details of round 4 of target selection.  The number of M. pneumoniae ORFs 
eliminated by each filter is shown, and also expressed as a percentage of the number of 
targets entering the filter.  The final filter, for UGA codons, eliminated only the M. pneumoniae 
ORF but not other members of the family. 
 
Figure 2:  Percentage of Mycoplasma proteins covered at the coarse level by pre-BSGC, BSGC, 
and non-BSGC targets.  A timeline illustrates the relevant dates of PDB deposition.  Detailed 
data, including fine coverage and per-residue coverage, is given in Table III.  Eight structures 
solved prior to the formal establishment of the BSGC which were selected as BSGC targets in 
round 1 are included as BSGC targets rather than pre-BSGC targets, even though they were 
deposited into the PDB prior to 1 September 2000. 
 
Figure 3:  Percentage and number of BSGC targets that have been stopped, over time.  The 
percentage stopped is calculated as a fraction of the total number of targets that had been 
selected prior to each date. 
 
Figure 4:  Target stage at time of deselection, for the 178 deselected targets.  Five targets 
were deselected due to experimental difficulty, 86 because the BSGC solved a homologous 
target, and 87 because the structure of a homologous protein was solved elsewhere. 
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 Table I:  Methods used in BSGC target selection rounds.  The number of targets selected in 
each round is given in parentheses next to the description of the round, followed by the 
numbers solved and active (neither solved nor stopped) as of 13 July 2004.  The “Max 
Targets per MP” column refers to the maximum number of protein targets selected for each 
M. pneumoniae protein that met the criteria for that round.  In round 5, the maximum number 
of targets per M. pneumoniae ORF was theoretically limited to 10 as in round 4, but was 
actually 1 since these proteins did not have homologs in other bacteria. 
 
Round 
(Date 
Selected) 
Description 
(number of targets / 
number solved / 
currently active) 
Method of detecting 
known structure 
Standard for eliminating less 
tractable proteins 
Max 
Targets 
per MP 
1 
(various 
dates) 
Preliminary and 
manually selected 
targets 
(163/32/42) 
ad hoc ad hoc ad hoc 
2  
(28 Aug 
2001) 
First automated 
set (92/10/44) 
PSI-BLAST (v. 2.2.1, 
snr dated  
30 July 2001, 
h=0.005,  
e=10-4) 
Any predicted coiled coil, 
low complexity, and 
transmembrane regions.  
Length > 400 AA.  For 
Mycoplasma genes, max of 
1 internal UGA codon. 
4 
3 
(25 Feb 
2002) 
Second automated 
set (42/2/28) 
Pfam (v. 7.0, trusted 
cutoff), BLAST (v. 
2.2.1, e=10-1), PSI-
BLAST (v. 2.2.1, 
h=10-2, snr dated 30 
Nov 2001, e=10-1) 
Same as #2, but max 
length increased to 700, 
and thresholds for 
predicted coiled coil and 
low complexity regions 
raised to 20%. 
4 
4 
(7 Nov 
2002) 
Third automated 
set (93/7/43) 
 
Same as #3 Same as #3 10 
5  
(3 Mar 
2004) 
Multi-UGA targets 
(33/0/33) 
Same as #3 Same as #3, but allow 2-4 
internal UGA codons 
10 (1) 
6 
(22 Mar 
2004) 
First domain set 
(522/0/459) 
Applied to predicted 
domains.  Pfam (v. 
10.0, trusted cutoff), 
BLAST (v. 2.2.4, 
e=10-1), PSI-BLAST 
(v. 2.2.4, h=10-2, snr 
dated 26 Feb 2004, 
e=10-1).   
Same as #3, but applied to 
predicted domains.  No 
internal UGA codons 
allowed. 
10 
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Table II:  Coverage of Mycoplasma pneumoniae and Mycoplasma genitalium proteomes by 
structures solved prior establishment of the BSGC (Pre- BSGC row), and by all BSGC targets 
from the 6 rounds of target selection described in Table I.  Parallelism indicates the average 
number of targets homologous to each Mycoplasma pneumoniae or Mycoplasma genitalium protein 
that is covered by at least one target.  Residue coverage is calculated as a percentage of all 
residues, and as a percentage of the residues predicted to be HT-tractable and interesting (in 
parentheses). 
 
Fine Coverage of M. pneumoniae Coarse Coverage of M. pneumoniaeRound 
Proteins 
(687 total) 
Residues, % 
(239,722 total) 
Parallelism Proteins 
(687 total) 
Residues, % 
(239,722 total)  
Parallelism
Pre- 
BSGC 142 (20.7%) 16.5 (20.5) 
 
n/a 297 (43.2%) 35.2 (43.1) 
 
n/a 
1 272 (39.6%) 26.6 (32.7) 1.4 424 (61.7%) 47.2 (56.8) 1.7 
2 311 (45.3%) 30.7 (37.5) 3.2 467 (68.0%) 52.5 (62.6) 3.4 
3 340 (49.5%) 34.0 (41.3) 3.4 493 (71.8%) 56.1 (66.7) 3.6 
4 356 (51.8%) 35.7 (43.4) 3.5 495 (72.1%) 56.6 (67.3) 4.2 
5 399 (58.1%) 45.0 (54.1) 3.6 532 (77.4%) 64.8 (76.0) 4.3 
6 438 (63.8%) 48.2 (57.9) 8.6 550 (80.1%) 67.3 (78.7) 9.9 
Fine Coverage of M. genitalium Coarse Coverage of M. genitalium  
Proteins 
(486 total) 
Residues, % 
(175,930 total)
Parallelism Proteins 
(486 total) 
Residues, % 
(175,930 total) 
Parallelism
Pre- 
BSGC 137 (28.2%) 21.5 (26.6) 
 
n/a 262 (53.9%) 43.2 (52.4) 
 
n/a 
1 196 (40.3%) 29.4 (36.1) 1.6 311 (64.0%) 51.8 (62.0) 1.9 
2 215 (44.2%) 31.9 (39.1) 1.9 328 (67.5%) 54.6 (65.1) 2.2 
3 226 (46.5%) 33.8 (41.4) 1.9 340 (70.0%) 56.7 (67.6) 2.3 
4 231 (47.5%) 34.5 (42.2) 2.2 341 (70.2%) 57.0 (68.0) 2.9 
5 244 (50.2%) 38.4 (46.8) 2.2 354 (72.8%) 60.8 (72.1) 2.9 
6 283 (58.2%) 42.3 (51.5) 4.6 371 (76.4%) 64.0 (75.9) 5.7 
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Table III:  Coverage of Mycoplasma pneumoniae and Mycoplasma genitalium proteomes by 
structures solved prior to establishment of the BSGC (Pre- BSGC row), a cumulative total of 
structures solved at the BSGC and all structures solved prior to its establishment (+BSGC 
row), all structures solved outside the BSGC, including those solved prior to the 
establishment of the BSGC (Non- BSGC row), and by all current structures (Current).  A 
relative timeline of these four groups, and a histogram illustrating the coarse coverage 
statistics, are shown in Figure 2.  The Structures column indicates the number of entries 
from the knownstr database (i.e., PDB chains and structural genomics targets) that 
contributed to coverage in each row.  The latter database includes some redundant entries; 
e.g., a PDB entry, a PDB “on-hold” sequence, and a structural genomics target might all refer 
to the same protein.  Residue coverage is calculated as a percentage of all residues, and as a 
percentage of the residues predicted to be HT-tractable and interesting (in parentheses). 
 
Fine Coverage of M. pneumoniae Coarse Coverage of M. pneumoniaeSet 
Structures Proteins 
(687 total) 
Residues, % 
(239,722 total) 
Structures Proteins 
(687 total) 
Residues, % 
(239,722 total) 
Pre- 
BSGC 1453 142 (20.7%) 16.5 (20.5) 3270 297 (43.2%) 35.2 (43.1) 
+ BSGC 1569 162 (23.6%) 18.0 (22.4) 3452 326 (47.5%) 38.0 (46.5) 
Non- 
BSGC 4285 240 (34.9%) 28.7 (35.4) 9816 380 (55.3%) 48.9 (58.3) 
Current 4371 254 (37.0%) 29.8 (36.7) 9972 391 (56.9%) 49.8 (59.4) 
Fine Coverage of M. genitalium Coarse Coverage of M. genitalium  
Structures Proteins 
(486 total) 
Residues, % 
(175,930 total) 
Structures Proteins 
(486 total) 
Residues, % 
(175,930 total) 
Pre- 
BSGC 1305 137 (28.2%) 21.5 (26.6) 2945 262 (53.9%) 43.2 (52.4) 
+ BSGC 1405 154 (31.7%) 23.5 (29.0) 3124 287 (59.1%) 46.6 (56.4) 
Non- 
BSGC 3976 233 (47.9%) 37.4 (45.7) 8970 339 (69.8%) 60.4 (70.7) 
Current 4052 243 (50.0%) 38.6 (47.1) 9123 348 (71.6%) 61.5 (72.0) 
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Table IV:  Pfam-A families corresponding to BSGC targets, for which the BSGC solved the 
first or only structures of proteins in the family.  The PDB ID and date of PDB deposition are 
also shown.  Some structures solved prior to the formal establishment of the BSGC which 
were selected as BSGC targets in round 1 are included; these structures have PDB deposition 
dates prior to 1 September 2000. 
 
Families solved only at the BSGC 
Family 
Size 
Accession Family description PDB Date 
208 PF01895 PhoU family 1SUM 26 Mar 2004 
148 PF01513 ATP-NAD kinase 1SUW 26 Mar 2004 
143 PF01515 Phosphate acetyl/butaryl transferase 1R5J 10 Oct 2003 
92 PF02130 Uncharacterized protein family UPF0054 1OZ9 8 Apr 2003 
91 PF02381 Domain of unknown function UPF0040 1N0E 13 Oct 2002 
86 PF05175 Methyltransferase small domain 1DUS 18 Jan 2000 
73 PF04079 Putative transcriptional regulators (Ypuh-like) 1T6S 7 May 2004 
68 PF02635 DsrE/DsrF-like family 1JX7 5 Sep 2001 
31 PF04327 Protein of unknown function (DUF464) 1S12 5 Jan 2004 
26 PF04297 Putative HTH protein, YlxM/p13-like 1S70 29 Jan 2004 
Families solved first at the BSGC, but later solved elsewhere 
Family 
Size 
Accession Family description PDB Date 
617 PF00011 Hsp20/alpha crystallin family 1SHS 30 Jul 1998 
551 PF00467 KOW motif 1EIF 29 Jul 1998 
540 PF00582 Universal stress protein family 1MJH 4 Nov 1998 
387 PF01965 DJ-1/PfpI family 1G2I 19 Oct 2000 
150 PF02566 OsmC-like protein 1LQL 10 May 2002 
141   PF01351 Ribonuclease HII 1EKE 7 Mar 2000 
110 PF01812 5-formyltetrahydrofolate cyclo-ligase family 1SBQ 10 Feb 2004 
109 PF01709 Domain of unknown function DUF28 1LFP 11 Apr 2002 
105 PF01687 Riboflavin kinase / FAD synthetase 1MRZ 19 Sep 2002 
104 PF01725 Ham1 family 2MJP 27 Jan 1999 
99 PF02645 Uncharacterized protein, DegV family 1MGP 15 Aug 2002 
88 PF01746 tRNA (Guanine-1)-methyltransferase 1OY5 3 Apr 2003 
68 PF01287 Eukaryotic initiation factor 5A hypusine, 
DNA-binding OB fold 
1EIF 29 Jul 1998 
53 PF01269 Fibrillarin 1FBN 25 Apr 1999 
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Table V:  Impact of BSGC structures on coverage of other organisms.  Table IV lists 24 
Pfam-A families for which the BSGC solved the first or only structures of members of the 
family; this group of families is referred to as Pfam-BSGC.  Representation of those families 
in other proteomes, as well as Swiss-Prot (SP) and TrEMBL, is shown here. 
 
Proteome / Set Total # of 
proteins in set 
Proteins covered 
by Pfam-BSGC 
Total # of 
interesting and 
HT-tractable 
residues 
Residues covered 
by Pfam-BSGC 
A. thaliana 26,209 100 (0.4%) 9,613,448 13,733 (0.1%) 
C. elegans 22,602 37 (0.2%) 7,709,635 4,104 (0.1%) 
D. melanogaster 15,908 36 (0.2%) 6,848,099 5,495 (0.1%) 
E. coli 4,357 36 (0.8%) 1,101,407 5,898 (0.5%) 
H. sapiens 34,560 43 (0.1%) 12,502,002 5,003 (<0.1%) 
M. jannaschii 1,777 20 (1.1%) 410,871 2495 (0.6%) 
M. tuberculosis 3,877 33 (0.9%) 1,050,708 5,649 (0.5%) 
M. musculus 38,795 66 (0.2%) 13,397,269 7,013 (0.1%) 
R. norvegicus 27,479 40 (0.1%) 8,985,290 3,962 (<0.1%) 
Swiss-Prot 127,046 1,122 (0.9%) 38,898,937 162,049 (0.4%) 
SP+ TrEMBL 984,936 3,737 (0.4%) 249,695,988 532,320 (0.2%) 
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Table VI:  Predicted biochemical and cellular roles of BSGC targets and ORFs from M. 
pneumoniae and M. genitalium.  The first column shows the TIGR major role categories. The 
second column shows the total number of targets annotated in each role, along with the 
number solved and the number of currently active targets remaining.  The last two columns 
show annotations of Mycoplasma proteomes:  the first number in each column is the total 
number of proteins in the proteome in that role, the second is the number with some 
structural coverage at the “coarse” level, and the third is the number of proteins with “fine” 
structural coverage. 
 
Proteomes:  # of proteins 
(total / coarse / fine) 
TIGR Role Targets /  
# solved / 
# active M. pneumoniae M. genitalium 
Amino acid biosynthesis 1/1/0 1/1/1 0/0/0 
Biosynthesis of cofactors, prosthetic groups, 
and carriers 
10/4/5 7/7/5 5/5/3 
Cell envelope 60/0/57 50/15/0 28/7/1 
Cellular processes 16/0/10 6/6/3 6/6/4 
Central intermediary metabolism 11/2/1 8/8/7 7/7/7 
DNA metabolism 121/1/119 36/29/17 28/26/18 
Energy metabolism 28/2/9 37/37/27 32/32/25 
Fatty acid and phospholipid metabolism 11/0/3 9/7/1 8/6/1 
Protein fate 24/2/18 22/21/16 20/19/14 
Protein synthesis 69/4/51 77/74/70 89/86/75 
Purines, pyrimidines, nucleosides, and 
nucleotides 
14/1/7 20/20/17 17/17/15 
Regulatory functions 33/3/23 5/5/4 5/5/3 
Signal transduction 0/0/0 0/0/0 0/0/0 
Transcription 24/5/14 11/10/9 13/12/11 
Transport and binding proteins 18/0/14 35/24/20 33/23/21 
Hypothetical proteins 201/15/120 88/34/14 160/75/26 
Unclassified function 225/4/206 162/51/18 1/0/0 
Unknown function 58/1/43 12/11/7 12/12/11 
* No annotation 24/1/21 101/31/18 22/10/8 
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Chandonia et al, Figure 1
Some known 3D structure: 412 (61%) 
Too long: 21 (8%)
X X
Remaining families:  82 386 total targets in round 4
677 MP ORFs, and homologs from other prokaryotes 
Transmembrane: 99 (41%)
Coiled coil: 5 (3%)
Low complexity: 11 (8%)
Too many internal UGA codons:  65 (50%)
(only eliminates MP ORF)
Chandonia et al, Figure 2
Figure 2:  Coarse Coverage of Mycoplasma  proteomes
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Figure 3:  Percentage and number of BSGC targets stopped
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Figure 4:  Stage and reason why targets were deselected
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Target Organisms 
 The BSGC has selected targets from the prokaryotes shown in Table S1.  The current 
list may be found on our website, http://www.strgen.org/ 
 
Experimental Attrition Rates 
 Table S2 shows the experimental status of BSGC targets as of 13 July 2004.  As 
shown in Figure 4, only five of the targets deselected prior to 1 June 2004 were stopped due 
to experimental difficulties alone; most were stopped due to the BSGC or another group 
solving a homolog of the target.  Therefore, the “In Progress” column of Table S2 
emphasizes the current stages of the 649 targets that have were selected but not deselected. 
 As the data in Table S2 represents a snapshot in time only 4 months after the 
selection of the majority of the targets, the distribution of stages of these targets is too 
preliminary to be informative.  However, the rightmost column in Table S2 contains a subset 
of data on the targets from the 3 automated rounds (2-4) of target selection, which were 
chosen between 28 August 2001 and 7 Nov 2002, and have been studied for at least 20 
months.  Of these 227 targets, 19 (8%) have been solved, and approximately half (115/227, 
or 51%) are still active.  For these targets, the major experimental bottleneck appears to be 
crystallization.  Of the 115 active targets, 43 were purified but not successfully crystallized, 
and 10 more have not achieved diffraction quality crystals.  Overall, 25 of 78 purified 
proteins (32%) yielded sufficiently good crystals for diffraction.  The next most significant 
bottleneck was purification of soluble proteins:  of 102 soluble proteins, 78 (76%) were 
successfully purified. 
 A more recent analysis of the domain targets (round 6), was performed using results 
from 10 Feb 2005.  This data, in Table S3, is instructive for comparing experimental 
bottlenecks of domain and full-length targets.  In the 7 months between the snapshots of 
Table S2 and S3, additional structures were solved for the full-length targets selected in 
rounds 2-4, and 30 more targets in this group were stopped due to homologs being solved at 
the BSGC or elsewhere.  However, the major experimental bottlenecks for this group appear 
qualitatively similar to those indicated by the results from 13 July 2004.  In contrast, although 
most of the domain targets were successfully cloned by 10 Feb 2005, expression of soluble 
protein has been a significant bottleneck for these targets.  About one third (121 of 361) of 
the domain targets cloned were not successfully expressed, and over half of the expressed 
clones (127 of 240) were not successfully solublized.  We expect that many of these cases are 
due to incorrectly predicted domain boundaries or domains that are unable to fold 
independently. 
 These results are preliminary and must be treated with caution, as there are 
indications that some of the recent experimental bottlenecks in the domain target set may be 
the result of using a new fusion tag.  Direct comparison with other centers is difficult, as 
there are differing interpretations of the standards for targets reaching most of the 
experimental stages.  However, we plan to perform a more complete analysis of bottlenecks, 
including comparison to other structural genomics centers, after more experimental work 
has progressed on the domain target set.
Table S1:  Organisms from which BSGC targets were chosen. 
Organism (Strain) Name Number of Targets 
Aeropyrum pernix 8 
Allochromatium vinosum 3 
Aquifex aeolicus 39 
Archaeoglobus fulgidus 24 
Bacillus halodurans 37 
Bacillus subtilis 35 
Borrelia burgdorferi 1 
Campylobacter jejuni 3 
Chlorobium tepidum TLS 16 
Clostridium acetobutylicum 6 
Deinococcus radiodurans 10 
Escherichia coli K12 23 
Escherichia coli O157:H7 1 
Haemophilus influenzae Rd 5 
Halobacterium sp. NRC-1 27 
Helicobacter pylori 26695 5 
Helicobacter pylori J99 2 
Methanococcus jannaschii 57 
Methanothermobacter thermautotrophicus 23 
Mycoplasma genitalium 97 
Mycoplasma pneumoniae 319 
Neisseria meningitidis MC58 4 
Neisseria meningitidis Z2491 3 
Nostoc sp. PCC 7120 5 
Pseudomonas aeruginosa 7 
Pyrococcus furiosus DSM 3638 8 
Pyrococcus horikoshii 11 
Salmonella typhimurium LT2 3 
Staphylococcus aureus subsp. aureus Mu50 9 
Streptococcus agalactiae 7 
Streptococcus pneumoniae R6 6 
Streptococcus pneumoniae TIGR4 4 
Streptococcus pyogenes 13 
Streptomyces coelicolor A3(2) 1 
Sulfolobus solfataricus 7 
Thermoplasma acidophilum 10 
Thermoplasma volcanium 9 
Thermotoga maritima 72 
Ureaplasma urealyticum 14 
Vibrio cholerae 6 
Xanthomonas campestris pv. campestris str. ATCC 33913 5 
Xylella fastidiosa 1 
Xylella fastidiosa 9a5c 2 
Table S2:  Current experimental stages of active and solved BSGC targets, as of 13 July 2004.  
The “Number of targets” column shows the total number of targets that have reached each 
experimental stage.  In the “In Progress” columns, the first 8 rows show the number of 
targets at each stage that have not been deselected, and have not progressed to a subsequent 
stage.  The current statistics may be found online at http://www.strgen.org/ 
 
Experimental Stage Number of 
Targets, 
All rounds 
Targets in 
Progress, 
All rounds 
Targets in 
Progress, 
Rounds 2-4 only 
Selected 945 231 12 
Cloned 640 89 16 
Expressed 499 119 4 
Soluble 366 117 24 
Purified 194 66 43 
Crystallized 84 19 10 
Diffraction quality crystals 60 7 5 
Traceable map 49 1 1 
Crystal structure 48 targets / 
66 structures 
48 targets / 
66 structures 
18 targets / 
19 structures 
NMR structure 3 targets / 
3 structures 
3 targets / 
3 structures 
1 target / 
1 structure 
Deselected 245 245 93 
 
Table S3:  Current experimental stages of active and solved BSGC targets, from target 
selection rounds described in this report, as of 10 Feb 2005.  The “Number of targets” 
column shows the total number of targets that have reached each experimental stage.  In the 
“In Progress” columns, the first 8 rows show the number of targets at each stage that have 
not been deselected, and have not progressed to a subsequent stage.  The current statistics 
may be found online at http://www.strgen.org/ 
 
Experimental Stage Number of 
Targets, 
All rounds 
Targets in 
Progress, 
Rounds 2-4 only 
Targets in 
Progress, 
Round 6 only 
Selected 952 11 20 
Cloned 820 9 121 
Expressed 597 2 127 
Soluble 420 14 78 
Purified 239 35 30 
Crystallized 94 9 2 
Diffraction quality crystals 69 2 2 
Traceable map 55 0 0 
Crystal structure 55 targets / 
81 structures 
21 targets / 
30 structures 
1 target / 
1 structure 
NMR structure 3 targets / 
3 structures 
1 target / 
1 structure 
0 
Deselected 356 123 141 
 
